drugset / Trial / NCT00920517

Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine

NCT00920517 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.

Timeline

Start
2009-01
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator rDEN2/4delta30(ME) Vaccine 1000 unknown Other

Indications